Tranzone secures GSK deal

Published: 8-Dec-2011
Finance Logistics

Will store various products in Jebel Ali for distribution to the Gulf and Near East Region

Tranzone Logistics, a subsidiary of Saudia Arabia-based Banaja Holdings, is to store various products for GlaxoSmithKline in its new warehouse in Jebel Ali for distribution to the Gulf and Near East Region.

The deal was signed during the opening ceremony for Tranzone’s new facility.

GSK will occupy a major part of Tranzone’s warehouse, contributing approximately 25% of revenue in 2012.

Tranzone said GSK had demanded top-of-the-range facilities and back up to protect products at all times and in all circumstances. Emphasis had also been placed on physical security such as access control and fire prevention and process quality.

Tranzone’s state-of-the-art 3PL warehouse at JAFZA in Jebel Ali provides storage, inventory management, as well as purchasing and re-invoicing to the distributor, all at one convenient location. The firm says it is able to store pharmaceuticals in an ideal environment, and its integrated system better links principals with distributors, removes layers of inefficiency and cuts costs while improving service quality.

See more

You may also like

Manufacturing

Banaja takes majority stake in DEEF Pharmaceutical

Read more
Aims to expand and diversify DEEF facility in Saudi Arabia

Trending Articles

  1. Hovione announces leadership transition and interim Co-CEO structure Co-CEOs for the transition period, António Almeida and Dr. Marco Gil, bring combined 40 years of experience with Hovione to their new role
  2. Cambridge biotech Verinnogen secures £500k CPI investment to advance cancer drug development The investment will advance a handheld device delivering more precise and reproducible tumour size measurements in preclinical oncology research, addressing variability in existing techniques that can slow drug development and necessitate costly repeat studies
  3. Lonza delivers strong H1 2025 performance Lonza delivers strong H1 2025 performance and upgrades 2025 full-year CDMO sales and margin outlook
  4. Adragos Pharma appoints Kostas Rengis as Chief Executive Officer Munich, Germany – May 7th, 2026 – Adragos Pharma, a global contract development and manufacturing organisation (CDMO), today announced the appointment of Konstantinos (Kostas) Rengis as its new Chief Executive officer, succeeding Dr. Andreas Raabe, who founded the company and has led it over the past six years
  5. Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model

Upcoming event

Cleanroom Technology Conference UK

20-21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Banaja takes majority stake in DEEF Pharmaceutical

Aims to expand and diversify DEEF facility in Saudi Arabia
Manufacturing

Andelyn Biosciences launches LVV Curator platform, bringing proven viral vector platform pedigree to Lentiviral Vector manufacturing for cell therapies

New platform leverages the established Curator platform methodology to industrialise Lentivirus processes from concept to clinic
Manufacturing

Bora Group to acquire MacroGenics’ manufacturing operations and CDMO business

The purchase will hand the Group a biologics drug substance manufacturing facility and a warehousing centre in Maryland, which Bora plans to use in cooperation with Tanvex Biopharma to scale its end-to-end biologics platform
Finance

Cambridge biotech Verinnogen secures £500k CPI investment to advance cancer drug development

The investment will advance a handheld device delivering more precise and reproducible tumour size measurements in preclinical oncology research, addressing variability in existing techniques that can slow drug development and necessitate costly repeat studies
Manufacturing

Adragos Pharma appoints Kostas Rengis as Chief Executive Officer

Munich, Germany – May 7th, 2026 – Adragos Pharma, a global contract development and manufacturing organisation (CDMO), today announced the appointment of Konstantinos (Kostas) Rengis as its new Chief Executive officer, succeeding Dr. Andreas Raabe, who founded the company and has led it over the past six years
Research & Development

Syngene strengthens leadership team with two key appointments to support next phase of growth

Abhijit Zutshi joins as CCO and Maninder Kapoor Puri as CHRO. India/U.S./UK, 1 May 2026: Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the Abhijit Zutshi as Chief Commercial Officer (CCO) and Maninder Kapoor Puri as Chief Human Resources Officer (CHRO), effective 1 May 2026
Manufacturing

Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair

Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Subscribe now